Funded Biotechnology Startups in Japan
Disclosed deal sizes in this Japan biotechnology slice range from $120K (GoldenHarvest, 2026-06-08) up to $443M (Scohia Pharma, 2026-05-28), where Scohia’s…
Disclosed deal sizes in this Japan biotechnology slice range from $120K (GoldenHarvest, 2026-06-08) up to $443M (Scohia Pharma, 2026-05-28), where Scohia’s round dwarfs every other disclosed amount by a wide margin. Most other disclosed checks cluster below the $20M mark, with Restore Vision at $8M (2026-04-15) and Arrowsmith at $7M (2026-06-22) among the larger non-outlier rounds.
Geographically, the list is heavily Tokyo-centered: Tokyo appears for LIFESCAPES (2026-06-15, $4M), Dioseve (2026-06-11, $6M), xCARE (2026-06-09, undisclosed), GoldenHarvest (2026-06-08, $120K), BitBiome (2026-05-26, undisclosed), Gel-Coat Biomaterials (2026-04-22, $1M), Molmir (2026-04-22, $2M), Restore Vision (2026-04-15, $8M), Think Nature (2026-04-01, $2M is Okinawa/Urasoe, not Tokyo), and more—while non-Tokyo entries include Sonire Therapeutics (Shinjuku/Yamanashi, 2026-06-17, $13M) and Metagen Therapeutics (Tsuruoka, 2025-09-10, $16M). Temporally, rounds span 2025-09-10 through 2026-06-22, and 10 of 14 entries fall in June 2026. Series labels are split: five entries are “Series Unknown” and three are explicitly labeled (Series A/B) or otherwise, with two additional rows marked undisclosed ($ undisclosed for xCARE and Epsilon Molecular Engineering, and another undisclosed for BitBiome).
Most recent rounds
14 shownRelated listings
Frequently asked
Which recent disclosed round is an outlier, and how far above the rest is it?
Scohia Pharma’s $443M round on 2026-05-28 is the largest disclosed amount in the 14-row view and dwarfs the next-largest disclosed check, $16M for Metagen Therapeutics on 2025-09-10; the rest of the disclosed amounts (e.g., Arrowsmith $7M on 2026-06-22, Restore Vision $8M on 2026-04-15) sit well below that scale.
How concentrated are rounds in time, and what does that imply for recency?
Ten of the 14 rounds are dated in June 2026, including entries from 2026-06-22 (Arrowsmith, $7M) down to 2026-06-08 (GoldenHarvest, $120K). The oldest row shown is 2025-09-10 (Metagen Therapeutics, $16M), so the visible pipeline is front-loaded into the most recent months.
Is Tokyo over-represented compared with other cities/regions?
Yes, Tokyo (including Tokyo, Tokyo) appears repeatedly across dates and amounts: LIFESCAPES (2026-06-15, $4M), Dioseve (2026-06-11, $6M), GoldenHarvest (2026-06-08, $120K), Gel-Coat Biomaterials (2026-04-22, $1M), Molmir (2026-04-22, $2M), and Restore Vision (2026-04-15, $8M). Non-Tokyo entries include Scohia Pharma (Fujisawa, Kanagawa, 2026-05-28, $443M) and Metagen Therapeutics (Tsuruoka, 2025-09-10, $16M).
What stage/label mix dominates, and where do undisclosed amounts show up?
“Series Unknown” is common across the list (e.g., Sonire Therapeutics on 2026-06-17 for $13M; LIFESCAPES on 2026-06-15 for $4M; and Scohia Pharma on 2026-05-28 for $443M), while the explicitly labeled rounds are smaller in count. Separately, three entries carry “undisclosed” amounts—xCARE (2026-06-09), Epsilon Molecular Engineering (2026-05-28), and BitBiome (2026-05-26)—so disclosed-size comparisons exclude those rows.
Are there other large but not-largest checks worth comparing to the outlier?
Beyond Scohia Pharma’s $443M (2026-05-28), the largest disclosed amounts are $16M for Metagen Therapeutics (2025-09-10) and $13M for Sonire Therapeutics (2026-06-17). The next tier includes $8M Restore Vision (2026-04-15) and $7M Arrowsmith (2026-06-22), showing a steep drop-off after the top end.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.